AVE3085 Protects Coronary Endothelium from the Impairment of Asymmetric Dimethylarginine by Activation and Recoupling of eNOS

Purpose Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of eNOS and it is recognized as a risk factor for endothelial dysfunction in cardiovascular diseases. We investigated the effect of AVE3085, a newly developed transcription enhancer of eNOS, on ADMA-induced endothelial dysfunction in coronary arteries with underlying mechanisms explored.